Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Total Valuation
CytomX Therapeutics has a market cap or net worth of $40.07M. The enterprise value is -$8.74M.
Market Cap$40.07M
Enterprise Value-$8.74M
Share Statistics
CytomX Therapeutics has 80.10M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding80.10M
Owened by Insiders2.50%
Owened by Instutions28.88%
Financial Efficiency
CytomX Therapeutics’s return on equity (ROE) is -69.89 and return on invested capital (ROIC) is 62.20%.
Return on Equity (ROE)-6988.82%
Return on Assets (ROA)26.44%
Return on Invested Capital (ROIC)62.20%
Return on Capital Employed (ROCE)71.91%
Revenue Per Employee$1,160,529.412
Profits Per Employee$267,806.723
Employee Count119
Asset Turnover1.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytomX Therapeutics is 2.73. CytomX Therapeutics’s PEG ratio is >-0.01.
PE Ratio2.73
PS Ratio0.63
PB Ratio-190.73
Price to Fair Value-190.73
Price to FCF-1.00
Price to Operating Cash Flow-1.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of $138.10M and earned $31.87M in profits. Earnings per share was $0.38.
Revenue$138.10M
Gross Profit$137.18M
Operating Income$25.00M
Pretax Income$32.09M
Net Income$31.87M
EBITDA26.30M
Earnings Per Share (EPS)0.38
Cash Flow
In the last 12 months, operating cash flow was -$86.23M and capital expenditures -$310.00K, giving a free cash flow of -$86.54M billion.
Operating Cash Flow-$86.23M
Free Cash Flow-$86.54M
Free Cash Flow per Share-$1.08
Dividends & Yields
CytomX Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-99.50%
Earnings Yield36.64%
Stock Price Statistics
Beta2.02
52-Week Price Change-75.35%
50-Day Moving Average0.68
200-Day Moving Average1.02
Relative Strength Index (RSI)38.29
Average Volume (3m)2.92M
Important Dates
CytomX Therapeutics upcoming earnings date is May 7, 2025, After Close.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
CytomX Therapeutics as a current ratio of 1.25, with Debt / Equity ratio of -20.58
Current Ratio1.25
Quick Ratio1.25
Debt to Market Cap0.11
Net Debt to EBITDA-1.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CytomX Therapeutics has paid $223.00K in taxes.
Income Tax$223.00K
Effective Tax Rate0.70%
Enterprise Valuation
CytomX Therapeutics EV to EBITDA ratio is 2.33, with an EV/FCF ratio of -0.67.
EV to Sales0.42
EV to EBITDA2.33
EV to Free Cash Flow-0.67
EV to Operating Cash Flow-0.68
Balance Sheet
CytomX Therapeutics has $100.62M in cash and marketable securities with $9.38M in debt, giving a net cash position of -$91.24M billion.
Cash & Marketable Securities$100.62M
Total Debt$9.38M
Net Cash-$91.24M
Net Cash Per Share-$1.14
Tangible Book Value Per Share-$0.02
Margins
Gross margin is 100.00%, with operating margin of 18.10%, and net profit margin of 23.08%.
Gross Margin100.00%
Operating Margin18.10%
Pretax Margin23.24%
Net Profit Margin23.08%
EBITDA Margin18.10%
EBIT Margin18.10%
Analyst Forecast
The average price target for CytomX Therapeutics is $3.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.38
Price Target Upside537.74%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast36.45%
EPS Growth Forecast